Pharmacokinetics and Safety of Double-dose Dolutegravir When Used With Rifapentine for HIV-associated Tuberculosis

NCT05630872 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

30

Enrollment

NIH

Sponsor class

Conditions

HIV-associated Tuberculosis

Interventions

DRUG: Dolutegravir (DTG) 50 mg orally BID (~12 hours apart) plus TDF/3TC
DRUG: DTG 50 mg orally QD plus TDF/3TC
DRUG: 2HPZM
DRUG: 2HPM

Sponsor

National Institute of Allergy and Infectious Diseases (NIAID)

Collaborators

ViiV Healthcare
Mylan Inc.